| Literature DB >> 29486706 |
Vincent J Cornelisse1,2, Lei Zhang3,4, Matthew Law4, Marcus Y Chen3,5, Catriona S Bradshaw3,5, Clare Bellhouse3,5, Christopher K Fairley3,5, Eric P F Chow3,5.
Abstract
BACKGROUND: We aimed to describe anatomic site-specific concordance of gonococcal infections in partnerships of men who have sex with men (MSM).Entities:
Keywords: Disease transmission; Gonorrhea [C12.294.668.281.401]; Homosexuality [F01.145.802.975.500]; Infectious [N06.850.310]; Pharynx [A14.724]; Sexual partners [M01.778]
Mesh:
Year: 2018 PMID: 29486706 PMCID: PMC5830325 DOI: 10.1186/s12879-018-3003-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and behavioural characteristics of the 990 men who attended the Melbourne Sexual Health Centre with their male partner on the same day and were tested for both anorectal and pharyngeal gonococci by culture
| Characteristics | Median (IQR) | Yes/total; %yes |
|---|---|---|
| Age (years) | 28 (24 to 34) | – |
| Age difference (years) between partners | 4 (2 to 9) | – |
| HIV positive | – | 37/990 (4%) |
| Consistent condom use for RAI with RSP* | – | 350/905 (39%) |
| Consistent condom use for RAI with CSP* | – | 733/894 (82%) |
| Consistent condom use for IAI with RSP* | – | 335/899 (37%) |
| Consistent condom use for IAI with CSP* | – | 716/893 (80%) |
| Reported one or more CSP for AI in last 3 months | – | 440/990 (44%) |
| Number of CSP in last 3 months for those with CSP. | 3 (2 to 5) | – |
IQR = interquartile range; RAI = receptive anal intercourse; IAI = insertive anal intercourse; RSP = regular sexual partner; CSP = casual sexual partner
*Consistent condoms use at all times or no anal sex, in the last 3 months
Urethral gonorrhoea in partner 1, and associations with gonococcal infections by anatomic site in partner 2
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa | ||||
| Urethra -ve | Urethra +ve | Total | |||||
| P1 | Urethra -ve | 926 | 31 | 957 | 3.2% (2.2 to 4.6) | Ref | Ref |
| Urethra +ve | 31 | 2 | 33 | 6.1% (0.7 to 20.2) | 1.9 | 0.3 | |
| Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (0.4 to 8.4) | (0.1 to 1.8) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Pharynx -ve | Pharynx +ve | Total | |||||
| P1 | Urethra -ve | 942 | 15 | 957 | 1.6% (0.9 to 2.6) | Ref | Ref |
| Urethra +ve | 22 | 11 | 33 | 33.3% (18.0 to 51.8) | 31.4*** | 4.6* | |
| Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (13.0 to 76.1) | (1.2 to 17.1) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Rectum -ve | Rectum +ve | Total | |||||
| P1 | Urethra -ve | 931 | 26 | 957 | 2.7% (1.8 to 4.0) | Ref | Ref |
| Urethra +ve | 11 | 22 | 33 | 66.7% (48.2 to 82.0) | 71.6*** | 48.1*** | |
| Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (31.5 to 162.9) | (18.3 to 126.7) | |
These analyses include only participants who were tested at both the rectum and pharynx
aadjusted for gonorrhoea at other anatomic sites in partner 2, and for consistent condom use for insertive penile-anal sex with partner 2
*p < 0.05
**p < 0.01
***p < 0.001
Abbreviations: P1, “partner 1”; P2, “partner 2”; CI, confidence interval; OR, odds ratio; aOR
Pharyngeal gonorrhoea in partner 1, and associations with gonococcal infections by anatomic site in partner 2
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Urethra -ve | Urethra +ve | Total | |||||
| P1 | Pharynx -ve | 942 | 22 | 964 | 2.3% (1.4 to 3.4) | Ref | Ref |
| Pharynx +ve | 15 | 11 | 26 | 42.3% (23.4 to 63.1) | 31.4*** | 18.3*** | |
| Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (13.0 to 76.1) | (6.9 to 48.8) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Pharynx -ve | Pharynx +ve | Total | |||||
| P1 | Pharynx -ve | 944 | 20 | 964 | 2.1% (1.3 to 3.2) | Ref | Ref |
| Pharynx +ve | 20 | 6 | 26 | 23.1% (9.0 to 43.6) | 14.2*** | 2.5 | |
| Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (5.1 to 39.0) | (0.7 to 8.4) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Rectum -ve | Rectum +ve | Total | |||||
| P1 | Pharynx -ve | 927 | 37 | 964 | 3.8% (2.7 to 5.3) | Ref | Ref |
| Pharynx +ve | 15 | 11 | 26 | 42.3% (23.4 to 63.1) | 18.4*** | 8.9*** | |
| Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (7.9 to 42.8) | (3.2 to 24.6) | |
These analyses include only participants who were tested at both the rectum and pharynx
a adjusted for gonorrhoea at other anatomic sites in partner 2
*p < 0.05
**p < 0.01
***p < 0.001
Abbreviations: P1, “partner 1”; P2, “partner 2”; CI, confidence interval; OR, odds ratio; aOR
Rectal gonorrhoea in partner 1, and associations with gonococcal infections by anatomic site in partner 2
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Urethra -ve | Urethra +ve | Total | |||||
| P1 | Rectum -ve | 931 | 11 | 942 | 1.2% (0.6 to 2.1) | Ref | Ref |
| Rectum +ve | 26 | 22 | 48 | 45.8% (31.4 to 60.8) | 71.6*** | 63.9*** | |
| Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (31.5 to 162.9) | (24.7 to 165.6) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Pharynx -ve | Pharynx +ve | Total | |||||
| P1 | Rectum -ve | 927 | 15 | 942 | 1.6% (0.9 to 2.6) | Ref | Ref |
| Rectum +ve | 37 | 11 | 48 | 22.9% (12.0 to 37.3) | 18.4*** | 3.4 | |
| Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (7.9 to 42.8) | (1.0 to 12.2) | |
| P2 | % + ve (95% CI) | Crude OR | Adjusted ORa (95% CI) | ||||
| Rectum -ve | Rectum +ve | Total | |||||
| P1 | Rectum -ve | 910 | 32 | 942 | 3.4% (2.3 to 4.8) | Ref | Ref |
| Rectum +ve | 32 | 16 | 48 | 33.3% (20.4 to 48.4) | 14.2*** | 6.9*** | |
| Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (7.1 to 28.5) | (2.4 to 20.3) | |
These analyses include only participants who were tested at both the rectum and pharynx
aadjusted for gonorrhoea at other anatomic sites in partner 2, and for consistent condom use for receptive penile-anal sex with partner 2
*p < 0.05
**p < 0.01
***p < 0.001
Abbreviations: P1, “partner 1”; P2, “partner 2”; CI, confidence interval; OR, odds ratio; aOR